Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 1
Chunk 2
---
829
public shares outstanding.

On
January 9, 2024, our shareholders held an extraordinary general meeting (the “Longevity Business Combination Meeting”) and
voted in favor of approving the Longevity Business Combination.

On
June 26, 2024, pursuant to Section 11.1(a) of the Longevity Merger Agreement, the parties to the Longevity Merger Agreement entered into
a termination agreement (the “Termination Agreement”) pursuant to which the Longevity Merger Agreement was terminated effective
as of the date of the Termination Agreement. As a result of the Termination Agreement, the Longevity Merger Agreement is of no further
force and effect (other than certain customary limited provisions that survive the termination pursuant to the terms of the Longevity
Merger Agreement) and ancillary agreements entered into in connection with the Longevity Merger Agreement also automatically terminated
in accordance with their respective terms. As a result of the termination of the Longevity Merger Agreement, Holdco filed the Registration
Withdrawal Request on Form RW on August 9, 2024, to withdraw its registration statement on Form S-4, as amended, initially filed with
the SEC on March 29, 2023.

On
July 2, 2024, the Company issued a press release to announce that it entered into a letter of intent with Semnur, a wholly owned subsidiary
of Scilex Holding Company (“Scilex”), for a potential business combination.

1

On
July 10, 2024, our shareholders held an extraordinary general meeting (the “Second Extension Meeting”) to consider and vote
upon a proposal to amend, by way of special resolution, the Articles to extend the date by which we must (i) consummate a merger, share
exchange, asset acquisition, share purchase, reorganization or similar business combination involving Denali and one or more businesses
or entities; (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination;
and (iii) redeem 100% of the public shares from July 11, 2024 to April 11, 2025, by electing to extend the date to consummate an initial
business combination on a monthly basis for up to nine (9) times by an additional one month each time (such date as extended, the “Extended
Date”), unless the closing of the initial business combination has occurred, without the need for